anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was designed as a randomized cross-over multicenter clinical trial with participating centers from the CIBER de Fisiopatología de la Obesidad y Nutrición (CIBERobn), coordinated by the Hospital Universitario Ramón y Cajal, Madrid. The investigators included adult patients with the metabolic syndrome as defined by the Third Report of the National Cholesterol Education Program, Adult Treatment Panel III. All the subjects were Caucasian from European ancestry. Patients were randomized after the screening visit to one of two sequences: 1) Sequence 1 to receive fish consumption first and then no fish. The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Afterwards they continued for another 8 weeks with the same diet except for the avoidance of fish and any other seafood; 2) Sequence 2 for which they started with their previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood for the first 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
Here, we demonstrate that the spatial distribution of lipophilic cations governs the complexation pathways, serum stability, and biological performance of polymer-pDNA complexes (polyplexes). Previous research focused on block/statistical copolymers, whereas gradient copolymers, where the density of lipophilic cations diminishes (gradually or steeply) along polymer backbones, remain underexplored. We engineered gradient copolymers that combine the polyplex colloidal stability of block copolymers with the transfection efficiency of statistical copolymers. We synthesized length- and compositionally equivalent gradient copolymers (G1-G3) along with statistical (S) and block (B) copolymers of 2-(diisopropylamino)ethyl methacrylate and 2-hydroxyethyl methacrylate. We mapped how polymer microstructure governs pDNA loading per polyplex, pDNA conformational changes, and polymer-pDNA binding thermodynamics via static light scattering, circular dichroism spectroscopy, and isothermal titration calorimetry, respectively. While gradient steepness is a powerful design handle to improve polyplex physical properties, augment pDNA delivery capacity, and attenuate polycation-triggered hemolysis, microstructural contrasts did not elicit differences in complement activation.
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2-4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural similarities with medications which raise the risk of cardiac fibrosis and valvulopathy when taken regularly, including methysergide, pergolide, and fenfluramine. 3,4-Methylenedioxymethamphetamine, which is also reportedly used for microdosing, is likewise associated with heart valve damage when taken chronically. In this review, we evaluate the evidence that microdosing LSD, psilocybin, and other psychedelics for several months or more could raise the risk of cardiac fibrosis. We discuss the relationship between drug-induced cardiac fibrosis and the 5-HT2B receptor, and we make recommendations for evaluating the safety of microdosing psychedelics in future studies.
Participants will receive a placebo. Participants will take 1 serving of placebo/day.
OBJECTIVE: Obesity and excess adiposity are leading causes of metabolic and cardiovascular morbidity and mortality. Early identification of individuals at risk is key for preventive strategies. We examined the relationship between infant body composition (0-2 years of age) and later (>2 years) health outcomes using a systematic review.
DESIGN: We preregistered the study on PROSPERO (ID 288013) and searched Embase, PubMed and Cochrane databases for English language publications using the Medical Subject Headings (MeSH) terms 'infant' and 'body composition' and 'risk' between January 1946 and February 2022. We included studies which assessed infant body composition using predetermined in vivo methods other than body mass index (BMI).
RESULTS: We identified 6015 articles. After abstract screening to assess eligibility, we reviewed 130 full text publications. 30 were included in the final assessment and narrative synthesis. Meta-analysis was not possible due to heterogeneity of results. All 30 studies were of high quality and reported associations between infant body composition and 19 different health outcomes after 2 years of age. Outcome measurements ranged from 2 years to 16 years. The strongest associations were found between infant fat mass and later fat mass (7 studies), and later BMI (5 studies). For 11 of the outcomes assessed, there was no relationship to infant adiposity detected.
CONCLUSIONS: Current evidence, from a small number of studies, suggests a positive association between infant adiposity and future adiposity or BMI, but the validity of infant body composition as a biomarker of future health remains inconclusive. Carefully designed, standardised studies are required to identify the value of infant body composition for predicting later health.
TRIAL REGISTRATION: PROSPERO: 288013.
The invention provides a gel preparation. The gel preparation is prepared from the following components in percentage by weight: 0.5-15% of a cellulose derivative, 1-30% of glycerinum, 40-97% of deionized water, and the balance of one or more of polyethylene glycol and propylene glycol. The invention further provides an application of the gel preparation. The invention further provides an endoscope anesthesia gel preparation. The anesthesia gel preparation is prepared from the following components in percentage by weight: 0.2-3% of local anesthetics, 0.5-15% of cellulose derivative, 1-30% of glycerinum, 1-10% of propylene glycol, 0.01-1% of a preservative, 0.1-1% of a corrigent, and 40-97.2% of deionized water. The invention further provides an application of the endoscope anesthesia gel preparation. The gel preparation has the advantage that the cellulose derivative is taken as a gel substrate, so that the viscosity of the preparation can be increased, and is within the suitable range, and the preparation can be adhered on an endoscope apparatus, and also can slowly slide to the surface of the mucosa, so that the endoscope can easily enter the cavity, further, the pain of a patient during the diagnosis and treatment process is alleviated, and the operation by a doctor is convenient and rapid.
The protocol objectives are to enable prospective IRB review of research using human MRI scans and data collected under other branch protocols or extramural sources. By combining data from multiple sources, the investigators will be able to conduct analyses that require large numbers of observations that exceed the numbers collected in any single study. They will also be able to stratify and subgroup the combined samples in different ways to permit analyses that would otherwise not be possible. The study population consists of normal individuals and clinical groups of all ages. Clinical groups will be added by amendment, including patients suffering from schizophrenia, ADHD, autism, Klinefelter's disease, and Alzheimer's disease. The study design consists of 1) automated segmentation of MRI brain scans to obtain regional measurements of cortical thickness and volumetric measurements of brain structures including basal ganglia, 2) manual segmentation of brain structures and brain anomalies not amenable to automated segmentation such as Virchow-Robbins spaces, 3) correlation analyses between MRI brain measurements and available demographic (e.g. gender) and physiological (e.g. BMI) data, statistical analysis of group differences where the groups are defined by diagnosis, age, gender or by other potentially useful classification. Since all data were collected under other protocols there are no additional risks or benefits associated with this protocol. This protocol combines MRI data from disparate sources and can provide important information regarding factors that may affect the comparability of MRI scans obtained from different sites using various types of MRI scanners and pulse sequences to generate MRI images. It will also enable the analysis of specific subgroups with sufficient numbers of observations for meaningful statistics.
<P>PROBLEM TO BE SOLVED: To provide a film preparation for oral cavity application, having moderate strength with a simple composition, producible by a simple procedure, easily soluble in the oral cavity and miscible with food materials, or the like, at high mixing ratios.  <P>SOLUTION: This film preparation for oral cavity application is produced by compounding pregelatinized starch and/or pullulan, an enzymatically modified starch and a plasticizer. Usable examples of the pregelatinized starch are pregelatinized potato starch, pregelatinized tapioca starch and pregelatinized corn starch, and the enzymatically modified starch is the decomposition product of a hydroxyalkylated starch with an enzyme and the plasticizer is a polyhydric alcohol, a sugar alcohol or vegetable oil-and-fat. The film preparation for oral cavity application can further be compounded with a food material at a high compounding ratio, i.e. 40 mass% based on the total film preparation.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
No long-term studies in animals have been performed to evaluate the carcinogenic potential of isosorbide dinitrate. In a modified two–litter reproduction study, there was no remarkable gross pathology and no altered fertility or gestation among rats fed isosorbide dinitrate at 25 or 100 mg/kg/day.

: At oral doses 35 and 150 times the maximum recommended human daily dose, isosorbide dinitrate has been shown to cause a dose- related increase in embryotoxicity (increase in mummified pups) in rabbits. There are no adequate, well-controlled studies in pregnant women. Isosorbide dinitrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C
Granulation of vitamin A esters is effected by pouring molten vitamin A ester dropwise into a stirred organic liquid at -70 to -10 degrees C in which the ester is only slightly soluble at normal temperatures and whose density is lower than that of the ester, then separating the granules and drying them. The granules are easily formed without any variations due to chemical or mechanical influences, they are used in stable pharmaceutical formulations. Applicable to the acetate and palmitate of vitamin A. Solvents used are pref. alkanols (1-4C) and petroleum fractions b.p. 150 to 180 degrees C. Methanol is preferred.
The invention discloses a taditional Chinese medicine preparation used for treating children herpetic stomatitis. Herpetic stomatitis is considered as stomatosis or oral cavity ulcer in traditional Chinese medical science. Herpetic stomatitis is caused by inappropriate nursing and feeding, or caused by wind fever evil accumulating in spleen and affecting mouth and tongue. Oral sarcolemma is corroded, and oral mucosal ulceration is caused. Therefore, according to the invention, traditional Chinese medicine materials of Indian mockstrawberry, hemsley rockvine root tuber, chinese nut-gall, fiveleaf akebia fruit, propolis, redroot gromwell, common andrographis herb, nux vomica, and small centipeda herb are decocted into a decoction by using water. The decoction is taken by the children. As a result of clinical experiments, a total effective rate is 96.4%, and a good treatment effect is provided. The medicine preparation is suitable to be popularized.
The invention discloses a double-agent unidirectional slow-release skin repairing film and a preparation method and application thereof. The repair film includes a skin care base and a crosslinking agent. The skin-care matrix is smeared on the surface of skin, the cross-linking agent is sprayed, gel films with different densities can be formed on the surface of the smeared matrix layer, and the density degree of the films can be adjusted according to different skin requirements and environments, so that multiple purposes are realized. The double-agent unidirectional slow-release skin repairing film prepared by the invention has good antibacterial activity, skin-friendly property and biocompatibility, has wide application range, can be used for medical treatment such as wound dressing, and can also be used for skin care such as facial mask, hand film, neck film, and the like, and can achieve the purpose of skin repairing. The thickness, size, shape and air permeability of the double-agent unidirectional slow-release skin repairing film prepared by the invention can be regulated and controlled according to the individual requirements of users, and the action time is controllable. Meanwhile, the adhesive is soft and close to the skin, and after the adhesive is used, the substrate directly contacted with the skin is easy to uncover without tearing.
Salivary collection (SC) following surgery for oral cancer represents an underreported and unrecognized complication. Our study aimed to evaluate the efficacy of parotideomasseteric fascia flap (PFF) in preventing postoperative SC, comparing its effectiveness with other conventional methods. Between November 2019 and January 2023, 221 patients diagnosed with oral squamous cell carcinoma (OSCC) undergoing wide tumor ablation and neck dissection at Xiangya Hospital were included in the study. Patients were randomly allocated into four groups based on different intraoperative techniques to assess the preventive efficacy of PFF against SC. The incidence of SC in the PFF group was only 5.9%, which was significantly lower than the other three groups (p < 0.05). Among the 221 patients, the highest SC incidence occurred in buccal cancer cases (19.6%). However, in the PFF group, the incidence was not significantly different (9.5%; p > 0.05). Univariate analysis revealed a higher SC incidence associated with advanced clinical T stage (p = 0.02), N(+) stage (p = 0.01), low average serum albumin (SA) level (p = 0.00), and a large parotid wound (p = 0.00). In multivariate analysis, only average SA (p = 0.01; odds ratio [OR] 4.104; 95% CI 0.921-11.746) emerged as the most prevalent factor predisposing to SC. The utilization of PFF demonstrated a notable reduction in the incidence of postoperative SC, establishing it as a safe, effective, and convenient method for patients undergoing radical ablation for OSCC.
The SpO2 TR width is set narrower than the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
ORLISTAT is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. ORLISTAT is also indicated to reduce the risk for weight regain after prior weight loss. ORLISTAT is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 '5 " would have a BMI of 30.
Itraconazole showed no evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels up to 80 mg/kg/day (approximately 1 time the maximum recommended human dose [MRHD] of 400 mg/day based on body surface area comparisons). Male rats treated with 25 mg/kg/day (0.6 times the MRHD based on body surface area comparisons) had a slightly increased incidence of soft tissue sarcoma. These sarcomas may have been a consequence of hypercholesterolemia, which is a response of rats, but not dogs or humans, to chronic itraconazole administration. Female rats treated with 50 mg/kg/day (1.2 times the MRHD based on body surface area comparisons) had an increased incidence of squamous cell carcinoma of the lung (2/50) as compared to the untreated group. Although the occurrence of squamous cell carcinoma in the lung is extremely uncommon in untreated rats, the increase in this study was not statistically significant.

  
Itraconazole produced no mutagenic effects when assayed in DNA repair test (unscheduled DNA synthesis) in primary rat hepatocytes, in Ames tests with Salmonella typhimurium (6 strains) and Escherichia coli, in the mouse lymphoma gene mutation tests, in a sex-linked recessive lethal mutation (Drosophila melanogaster) test, in chromosome aberration tests in human lymphocytes, in a cell transformation test with C3H/10T½ C18 mouse embryo fibroblasts cells, in a dominant lethal mutation test in male and female mice, and in micronucleus tests in mice and rats. 

Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels of up to 40 mg/kg/day (1 time the MRHD based on body surface area comparisons), even though parental toxicity was present at this dosage level. More severe signs of parental toxicity, including death, were present in the next higher dosage level, 160 mg/kg/day (4 times the MRHD based on body surface area comparisons).
Risk Summary

Lisdexamfetamine is a pro-drug of dextroamphetamine. Based on limited case reports in published literature, amphetamine (d-or d, l-) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with lisdexamfetamine dimesylate.
The invention discloses a ganoderma lucidum product, its production method and edible method, belonging to the field of medicinal and health food. The product comprises ganoderma lucidum fruit body and ganoderma lucidum primordium that breed spores to maturity but do not release the spores yet as raw materials, wherein the raw materials have highest content of ganoderma lucidum beneficial ingredients and are most easily adsorbed. The raw materials are subject to washing, cutting and drying to prepare the product. The edible method of the product is characterized by chewing the product in the mouth, chewing out most beneficial ingredients and absorbing a part by the mouth, and swallowing the rest. By swallowing, the effective ingredients which are chewed out are easily digested and absorbed by the stomach and intestine. The production of the product is conducted at a low temperature which is a means for preventing the growth of bacteria and satisfies the requirement of keeping ganoderma lucidum beneficial ingredients. According to the production method disclosed herein, the natural beneficial ingredients of ganoderma lucidum can be completely kept, and especially immune protein of ganoderma lucidum is kept. The product disclosed herein has the characteristics of complete components, good efficiency, rapid absorption, and low cost.
Steatotic liver disease (SLD) is a burgeoning health problem predominantly associated with excessive alcohol consumption, which causes alcohol-related liver disease (ALD), and high caloric intake, which results in metabolic dysfunction-associated SLD (MASLD). The pathogenesis of ALD and MASLD, which can progress from steatohepatitis to more severe conditions such as liver fibrosis, cirrhosis, and hepatocellular carcinoma, is complicated by several factors. Recently, extracellular ATP and adenosine (Ado), as damage-associated molecular patterns, were reported to promote inflammation and liver fibrosis, contributing to SLD pathogenesis. Here, we explored the in vivo dynamics of hepatic extracellular ATP and Ado during the progression of steatohepatitis using a genetically encoded GPCR-activation-based sensor (GRAB) in zebrafish models. We established hepatocyte-specific GRABATP and GRABAdo in zebrafish and investigated the changes in in vivo hepatic extracellular ATP and Ado levels under ALD or MASLD conditions. Disease-specific changes in hepatocyte extracellular ATP and Ado levels were observed, clearly indicating a correlation between hepatocyte extracellular ATP/Ado dynamics and disease progression. Furthermore, clodronate, a vesicular nucleotide transporter inhibitor, alleviated the MASLD phenotype by reducing the hepatic extracellular ATP and Ado content. These findings provide deep insights into extracellular ATP/Ado dynamics in disease progression, suggesting therapeutic potential for ALD and MASLD.
The invention relates to a preparation method of the effective part of Hippophae rhamnoides. The method includes: crushing and screening aired Hippophae fruits or post-pressing Hippophae fruit residue, heating ethanol for reflux extraction, collecting extract, performing reduced-pressure recovery on the ethanol, condensing, enriching the condensate with macroporous resin, and vacuum-drying to obtain the total effective part of Hippophae rhamnoides. Hippophae rhamnoides contains 75-85% of the total effective part. The total effective part contains 35-50% of triterpene and 32-45% of total phenols. The results of in-vitro anti-oxidization and anti-bacteria experiments and bioactivity experiments show that the effective part of Hippophae rhamnoides is high in capacity of clearing free radicals in 2, 2-azino-bis(3-ethyl- benzothiazole-6-sulfonate) diammonium salt, high in inhibition on Staphylococcus aureus, and high in oxidation resistance and gram-positive bacterium inhibition. The product obtained by the preparation method is applicable to health foods, drugs, cosmetics or solid drink materials having the functions of protecting liver, lowering blood lipid, age defying, protecting gastric mucosa, antisepsis and anti-inflammation.